GI
CYTO

Gradient Investments’s Altamira Therapeutics Ltd CYTO Stock Holding History

Gradient Investments’s Portfolio CYTO Stock Details CYTO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-3
Closed -$1K – 1428
2022
Q1 		$1K Buy
+3
New +$1.45K ﹤0.01% 1153

Other funds holding CYTO

Group One Trading
Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
VPIM
Vanguard Personalized Indexing Management Oakland, California $10.2B AUM 34.45% 1-Year Est. Return
CG
Cutler Group San Francisco, California $307M AUM 45.11% 1-Year Est. Return

Gradient Investments's CYTO Position: Q2 2022 in Review

Gradient Investments sold out of Altamira Therapeutics Ltd (CYTO) in Q2 2022, closing a stake of 3 shares — an estimated $1K sold.

Gradient Investments first reported a position in CYTO in Q1 2022 and held it in 1 quarter. The position peaked at $1K in Q1 2022. 12 funds tracked by Wall St. Rank hold CYTO as of Q2 2022.

  • Gradient Investments reported no remaining Altamira Therapeutics Ltd position as of Q2 2022 after selling out during the quarter.
  • Gradient Investments sold 3 Altamira Therapeutics Ltd shares in Q2 2022, an estimated $1K.
  • Gradient Investments first reported a position in Altamira Therapeutics Ltd in Q1 2022 and held it in 1 quarter.
  • Gradient Investments's Altamira Therapeutics Ltd position peaked at $1K in Q1 2022.
  • 12 funds tracked by Wall St. Rank held Altamira Therapeutics Ltd as of Q2 2022.

Based on Gradient Investments's 13F filing for Q2 2022, filed 11 Jul 2022.